Cancer is the leading cause of death worldwide, and its treatment and outcomes have been
dramatically revolutionised by targeted therapies. As the most frequently mutated oncogene …

Metastasis has long been understood to lead to the overwhelming majority of cancer-related
deaths. However, our understanding of the metastatic process, and thus our ability to …

Abstract c-MYC (MYC) is a major driver of prostate cancer tumorigenesis and progression.
Although MYC is overexpressed in both early and metastatic disease and associated with …

During disease progression from primary towards metastatic prostate cancer (PCa), and in
particular bone metastases, the tumor microenvironment (TME) evolves in parallel with the …

Immune checkpoint blockade has been largely unsuccessful for the treatment of bone
metastatic castrate-resistant prostate cancer (mCRPC). Here, we report a combinatorial …

Background Frequent truncation mutations of the histone lysine N-methyltransferase KMT2C
have been detected by whole exome sequencing studies in various cancers, including …

Emerging evidence indicates that metabolic dysregulation drives prostate cancer (PCa)
progression and metastasis. AMP-activated protein kinase (AMPK) is a master regulator of …

Despite progress in prostate cancer (PC) therapeutics, distant metastasis remains a major
cause of morbidity and mortality from PC. Thus, there is growing recognition that preventing …

Unlike several other tumor types, prostate cancer rarely responds to immune checkpoint
blockade (ICB). To define tumor cell intrinsic factors that contribute to prostate cancer …

Despite standard hormonal therapy that targets the androgen receptor (AR) attenuates
prostate cancer (PCa) effectively in the initial stage, the tumor ultimately converts to …